NanoViricides is trading at $1.60 (+5.96%), gaining momentum after receiving approval for a Phase II Ebola trial and continued positive sentiment from analyst coverage. - The company announced today that it received ethics approval to proceed with a Phase II clinical trial for its lead drug candidate NV-387 Oral Gummies for Ebola in the Democratic Republic of Congo (DRC). - Investors also continue to respond to Noble Capital Markets' recent "Outperform" initiation, which set a bullish $6.00 price target for NNVC. - This move marks a recovery from a brief pullback on July 10, following a significant multi-day rally.